Rising pollution levels, rapid urban construction and a persistent tendency to manage chronic conditions like asthma at home, ...
Arizona author and journalist Terry Green Sterling has non-tuberculous mycobacterial pulmonary disease — an ailment that's ...
Laughing Water Capital highlights Theravance Biopharma as a special situation with significant upside potential. Read the ...
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April 14, 2026, the ...
Management plans to file for regulatory approval of "Tresmi" for PAH and ILD this year, with commercial launch targeted for next year. Tyvaso DPI platform enhancement -- Introduction of 80-microgram ...
In a bar, a poet meets the man behind the drug that saved his life — discovering how science, faith and chance created a future thought impossible.
Laughing Water Capital returned -4.5% in Q1 2026 while highlighting new high-conviction positions in Stride and Theravance.
Company to participate in oral showcase and poster presentation at leading forum for respiratory innovation IRVINE, Calif., April 7, 2026 /PRNewswire/ -- Qnovia, a clinical-stage company focused on ...
Investor's Business Daily on MSN
This drug stock nears a buy point, with profit set to explode
This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer its drug.
Worldwide Medical Supply announces the release of its Finger Pulse Oximeter, which provides instant SpO2 and pulse rate ...
AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results